Experiences with
Tyrosine745 public posts
Time to take a BiTE? Bispecific T-Cell Engagers (BiTEs)
ROR1 (Receptor tyrosine kinase-like Orphan Receptor 1) is a type I transmembrane protein and highly expressed on an array of haematological including CLL.
Want to take advantage of all our features? Just log in!
or
BTK inhibitor challenges by Dr. Nicole Lamanna
.
-
Nicole Lamanna, MD: With the advent of the BTK [Bruton tyrosine kinase] inhibitors and the fact that we’ve had many individuals on ibrutinib and now even acalabrutinib for many years, there’s no doubt that we’re starting to see some patients who develop resistant mutations to the covalent BTK inhibitors
CLL Society ASH 2021 Highlights from Day 2 of ASH 2021! Dr. Brian Koffman gives up updates
Brian Koffman gives up updates on the reversible non-covalently binding BTKi (Bruton’s tyrosine kinase inhibitor) pirtobrutinib (formerly LOXO-305), another reversable BTKi known as MK-1026 (formerly ARQ-531), 3-year follow-up data from the Ascend Trial: Acalabrutinib vs Rituximab plus Idelalisib